These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1723893)

  • 1. CSF chromogranin A-like immunoreactivity in schizophrenia. Assessment of clinical and biochemical relationships.
    van Kammen DP; Peters J; Yao J; Neylan T; Beuger M; Pontius E; O'Connor DT
    Schizophr Res; 1991 Dec; 6(1):31-9. PubMed ID: 1723893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia.
    van Kammen DP; Agren H; Yao JK; O'Connor DT; Gurklis J; Peters JL
    Am J Psychiatry; 1994 Mar; 151(3):379-84. PubMed ID: 7509126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal.
    van Kammen DP; Peters J; van Kammen WB; Nugent A; Goetz KL; Yao J; Linnoila M
    Biol Psychiatry; 1989 Jun; 26(2):176-88. PubMed ID: 2472177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF chromogranin A-like immunoreactivity in schizophrenia: relationships with REM latency and slow wave sleep.
    van Kammen DP; O'Connor DT; Neylan TC; Mouton A; Gurklis JA; Gilbertson MW; Peters JL
    Psychiatry Res; 1992 Apr; 42(1):53-63. PubMed ID: 1603881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Norepinephrine in acute exacerbations of chronic schizophrenia. Negative symptoms revisited.
    van Kammen DP; Peters J; Yao J; van Kammen WB; Neylan T; Shaw D; Linnoila M
    Arch Gen Psychiatry; 1990 Feb; 47(2):161-8. PubMed ID: 1689140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropeptide Y-like immunoreactivity in schizophrenia. Relationships with clinical measures.
    Peters J; Van Kammen DP; Gelernter J; Yao J; Shaw D
    Schizophr Res; 1990; 3(5-6):287-94. PubMed ID: 2178001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia.
    Pickar D; Breier A; Hsiao JK; Doran AR; Wolkowitz OM; Pato CN; Konicki PE; Potter WZ
    Arch Gen Psychiatry; 1990 Jul; 47(7):641-8. PubMed ID: 1694425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates.
    Breslin NA; Suddath RL; Bissette G; Nemeroff CB; Lowrimore P; Weinberger DR
    Schizophr Res; 1994 Apr; 12(1):35-41. PubMed ID: 7517175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reliability of norepinephrine and major monoamine metabolite measurements in CSF of schizophrenic patients.
    Linnoila M; Ninan PT; Scheinin M; Waters RN; Chang WH; Bartko J; van Kammen DP
    Arch Gen Psychiatry; 1983 Dec; 40(12):1290-4. PubMed ID: 6197036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF diazepam binding inhibitor and schizophrenia: clinical and biochemical relationships.
    van Kammen DP; Guidotti A; Kelley ME; Gurklis J; Guarneri P; Gilbertson MW; Yao JK; Peters J; Costa E
    Biol Psychiatry; 1993 Oct; 34(8):515-22. PubMed ID: 8274578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonidine treatment of schizophrenia: can we predict treatment response?
    van Kammen DP; Peters JL; van Kammen WB; Rosen J; Yao JK; McAdam D; Linnoila M
    Psychiatry Res; 1989 Mar; 27(3):297-311. PubMed ID: 2469097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia.
    van Kammen DP; Kelley ME; Gurklis JA; Gilbertson MW; Yao JK; Peters JL
    Arch Gen Psychiatry; 1995 Aug; 52(8):673-8. PubMed ID: 7543265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics.
    Hsiao JK; Colison J; Bartko JJ; Doran AR; Konicki PE; Potter WZ; Pickar D
    Arch Gen Psychiatry; 1993 Aug; 50(8):606-14. PubMed ID: 7688209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant monoamine metabolite levels in CSF and family history of schizophrenia. Their relationships in schizophrenic patients.
    Sedvall GC; Wode-Helgodt B
    Arch Gen Psychiatry; 1980 Oct; 37(10):1113-6. PubMed ID: 6158928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atrophy limited to the third ventricle in chronic schizophrenic patients. Report of a controlled series.
    Boronow J; Pickar D; Ninan PT; Roy A; Hommer D; Linnoila M; Paul SM
    Arch Gen Psychiatry; 1985 Mar; 42(3):266-71. PubMed ID: 2579616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide.
    Roy A; Ninan P; Mazonson A; Pickar D; Van Kammen D; Linnoila M; Paul SM
    Psychol Med; 1985 May; 15(2):335-40. PubMed ID: 2410941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between clinical and biochemical changes following neuroleptic treatment in schizophrenia.
    Cooper SJ; Leahey W; Liddle J; King DJ
    Schizophr Res; 1990; 3(4):261-7. PubMed ID: 1703780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melperone in the treatment of schizophrenia.
    Bjerkenstedt L
    Acta Psychiatr Scand Suppl; 1989; 352():35-9. PubMed ID: 2479227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoamine metabolite levels in cerebrospinal fluid and brain atrophy in lobotomized schizophrenic patients.
    Rimón R; Roos BE; Kampman R; Hyyppä S; Ranta P; Myllylä V
    Ann Clin Res; 1979 Feb; 11(1):25-9. PubMed ID: 453776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF of neuroleptic-naive first-episode schizophrenic patients: levels of biogenic amines, substance P, and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin).
    Miller C; Kirchmair R; Troger J; Saria A; Fleischhacker WW; Fischer-Colbrie R; Benzer A; Winkler H
    Biol Psychiatry; 1996 Jun; 39(11):911-8. PubMed ID: 9162202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.